Major histocompatibility complex class I–restricted cytotoxic T lymphocytes (CTLs) specific for epitopes within eight of the nine Epstein Barr Virus (EBV)-encoded latency-associated proteins have been recovered from EBV-infected human subjects by restimulation of lymphocytes in vitro. However, human class I–restricted CTL responses capable of recognizing EBNA-1 expressing cells were not detected in these studies. We have raised a murine CTL line that recognizes an epitope within EBNA-1 by immunizing mice with a vaccinia virus encoding a COOH-terminal EBNA-1 fragment. This novel CTL line was used to investigate whether the epitope (positions 509–517 in EBNA-1, presented through Kd) was presented to CTL by mouse cells expressing full-length EBNA-1 or a deletion mutant of EBNA-1, lacking the Glycine-Alanine (Gly-Ala)–rich region. Cells expressing full-length EBNA-1 are not lysed by the CTL line, whereas cells expressing the Gly-Ala deletion mutant are recognized. These results suggest that epitopes from full-length EBNA-1 are poorly presented, and that the Gly-Ala–rich region is responsible for this phenomenon. The inefficient presentation of EBNA-1–derived epitopes may explain the absence or rarity of EBNA-1–specific CTLs in vivo, a strategy that may allow EBV to maintain persistence within the immunocompetent host without being eliminated by CTLs.
Skip Nav Destination
Article navigation
2 February 1998
Brief Definitive Report|
February 02 1998
Murine Cytotoxic T Lymphocytes Recognize an Epitope in an EBNA-1 Fragment, but Fail to Lyse EBNA-1–expressing Mouse Cells
Siddhartha Mukherjee,
Siddhartha Mukherjee
From the *Molecular Immunology Group, Institute for Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, OX39DU, United Kingdom; ‡Microbiology and Tumor Biology Center (MTC), Karolinska Institute, 171 77, Stockholm, Sweden; §Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and ‖INM, Neuromed, Localita Camerelle, 86077, Pozzilli (IS), Italy
Search for other works by this author on:
Pankaj Trivedi,
Pankaj Trivedi
From the *Molecular Immunology Group, Institute for Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, OX39DU, United Kingdom; ‡Microbiology and Tumor Biology Center (MTC), Karolinska Institute, 171 77, Stockholm, Sweden; §Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and ‖INM, Neuromed, Localita Camerelle, 86077, Pozzilli (IS), Italy
Search for other works by this author on:
David M. Dorfman,
David M. Dorfman
From the *Molecular Immunology Group, Institute for Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, OX39DU, United Kingdom; ‡Microbiology and Tumor Biology Center (MTC), Karolinska Institute, 171 77, Stockholm, Sweden; §Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and ‖INM, Neuromed, Localita Camerelle, 86077, Pozzilli (IS), Italy
Search for other works by this author on:
George Klein,
George Klein
From the *Molecular Immunology Group, Institute for Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, OX39DU, United Kingdom; ‡Microbiology and Tumor Biology Center (MTC), Karolinska Institute, 171 77, Stockholm, Sweden; §Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and ‖INM, Neuromed, Localita Camerelle, 86077, Pozzilli (IS), Italy
Search for other works by this author on:
Alain Townsend
Alain Townsend
From the *Molecular Immunology Group, Institute for Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, OX39DU, United Kingdom; ‡Microbiology and Tumor Biology Center (MTC), Karolinska Institute, 171 77, Stockholm, Sweden; §Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and ‖INM, Neuromed, Localita Camerelle, 86077, Pozzilli (IS), Italy
Search for other works by this author on:
Siddhartha Mukherjee
From the *Molecular Immunology Group, Institute for Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, OX39DU, United Kingdom; ‡Microbiology and Tumor Biology Center (MTC), Karolinska Institute, 171 77, Stockholm, Sweden; §Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and ‖INM, Neuromed, Localita Camerelle, 86077, Pozzilli (IS), Italy
Pankaj Trivedi
From the *Molecular Immunology Group, Institute for Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, OX39DU, United Kingdom; ‡Microbiology and Tumor Biology Center (MTC), Karolinska Institute, 171 77, Stockholm, Sweden; §Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and ‖INM, Neuromed, Localita Camerelle, 86077, Pozzilli (IS), Italy
David M. Dorfman
From the *Molecular Immunology Group, Institute for Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, OX39DU, United Kingdom; ‡Microbiology and Tumor Biology Center (MTC), Karolinska Institute, 171 77, Stockholm, Sweden; §Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and ‖INM, Neuromed, Localita Camerelle, 86077, Pozzilli (IS), Italy
George Klein
From the *Molecular Immunology Group, Institute for Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, OX39DU, United Kingdom; ‡Microbiology and Tumor Biology Center (MTC), Karolinska Institute, 171 77, Stockholm, Sweden; §Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and ‖INM, Neuromed, Localita Camerelle, 86077, Pozzilli (IS), Italy
Alain Townsend
From the *Molecular Immunology Group, Institute for Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, OX39DU, United Kingdom; ‡Microbiology and Tumor Biology Center (MTC), Karolinska Institute, 171 77, Stockholm, Sweden; §Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and ‖INM, Neuromed, Localita Camerelle, 86077, Pozzilli (IS), Italy
Address correspondence to Siddhartha Mukherjee, Molecular Immunology Group, Institute for Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, OX39DU, UK.
S. Mukherjee was supported by the Rhodes Trust. P. Trivedi was supported by a grant from the Istituto Superiore di Sanita, Italy.
Received:
May 09 1997
Revision Received:
September 08 1997
Online ISSN: 1540-9538
Print ISSN: 0022-1007
1998
J Exp Med (1998) 187 (3): 445–450.
Article history
Received:
May 09 1997
Revision Received:
September 08 1997
Citation
Siddhartha Mukherjee, Pankaj Trivedi, David M. Dorfman, George Klein, Alain Townsend; Murine Cytotoxic T Lymphocytes Recognize an Epitope in an EBNA-1 Fragment, but Fail to Lyse EBNA-1–expressing Mouse Cells . J Exp Med 2 February 1998; 187 (3): 445–450. doi: https://doi.org/10.1084/jem.187.3.445
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement